Alterity Therapeutics (NASDAQ:ATHE) Research Coverage Started at Craig Hallum

Craig Hallum initiated coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a report published on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $12.00 price target on the stock.

Several other brokerages have also issued reports on ATHE. Zacks Research upgraded shares of Alterity Therapeutics to a “hold” rating in a research note on Wednesday, June 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Friday, July 17th. LADENBURG THALM/SH SH started coverage on Alterity Therapeutics in a report on Tuesday, June 16th. They set a “buy” rating and a $10.00 price objective for the company. Finally, JonesTrading started coverage on Alterity Therapeutics in a research report on Tuesday, June 30th. They issued a “buy” rating and a $16.00 target price for the company. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alterity Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Alterity Therapeutics Stock Performance

NASDAQ ATHE opened at $4.63 on Tuesday. Alterity Therapeutics has a 52-week low of $2.66 and a 52-week high of $5.89. The company has a 50-day simple moving average of $4.81 and a 200 day simple moving average of $4.16.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC bought a new position in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics at the end of the most recent reporting period. 2.14% of the stock is currently owned by institutional investors and hedge funds.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.